Opiant Pharmaceuticals (OPNT) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-38193
Entity Registrant Name	OPIANT PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4744124
Entity Address, Address Line One	233 Wilshire Blvd.
Entity Address, Address Line Two	Suite 280,
Entity Address, City or Town	Santa Monica,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90401
City Area Code	310
Local Phone Number	598-5410
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,720,285
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	OPNT
Security Exchange Name	NASDAQ
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001385508
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 35,284,595	$ 48,251,336
Marketable securities	15,044,750	0
Accounts receivable	15,425,938	8,910,975
Prepaid and other current assets	2,121,145	1,936,842
Total current assets	67,876,428	59,099,153
Other assets
Property and equipment - net	93,519	171,190
Right of use assets - operating leases	997,777	278,455
Patents and patent applications - net	11,971	13,000
Other non-current assets	0	1,051,234
Total assets	68,979,695	60,613,032
Current liabilities
Accounts payable and accrued expenses	2,580,904	2,966,479
Accrued salaries and wages	1,347,552	908,516
Royalty payable	3,136,677	1,908,072
Deferred revenue	0	354,756
Operating leases	287,139	282,421
Total current liabilities	7,352,272	6,420,244
Long-term liabilities
Operating leases - long term	716,343	0
Convertible debt, net of unamortized discount	18,905,723	18,700,546
Total long-term liabilities	19,622,066	18,700,546
Total liabilities	26,974,338	25,120,790
Stockholders' equity
Common stock; par value $0.001; 200,000,000 shares authorized; 4,618,221 and 4,258,105 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	4,618	4,259
Additional paid-in capital	104,460,194	100,203,979
Accumulated other comprehensive loss	(26,850)	(26,931)
Accumulated deficit	(62,432,605)	(64,689,065)
Total stockholders' equity	42,005,357	35,492,242
Total liabilities and stockholders' equity	$ 68,979,695	$ 60,613,032

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	4,618,221	4,258,105
Common stock, shares outstanding (in shares)	4,618,221	4,258,105

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Royalty revenue	$ 14,041,006	$ 8,600,811	$ 27,688,713	$ 19,056,999
Grant and contract revenue	2,298,055	505,265	6,296,542	644,195
Total revenue	16,339,061	9,106,076	33,985,255	19,701,194
Operating expenses
General and administrative	3,378,707	2,729,098	8,758,601	8,138,571
Research and development	4,881,398	2,783,452	12,119,088	4,762,749
Sales and marketing	1,059,649	914,349	3,080,211	3,737,793
Royalty expense	3,058,865	1,951,947	6,145,057	4,288,701
Total operating expenses	12,378,619	8,378,846	30,102,957	20,927,814
Income (loss) from operations	3,960,442	727,230	3,882,298	(1,226,620)
Other income (expense)
Interest income	3,498	3,922	10,334	92,015
Interest expense	(547,296)	0	(1,626,273)	0
Gain (loss) on foreign exchange	455	(6,178)	(9,899)	(2,269)
Total other income (expense)	(543,343)	(2,256)	(1,625,838)	89,746
Income (loss) before income taxes	3,417,099	724,974	2,256,460	(1,136,874)
Income tax (expense)	0	0	0	(39,000)
Net income (loss)	3,417,099	724,974	2,256,460	(1,175,874)
Other comprehensive income (loss):
Foreign currency translation adjustment	(7,974)	196,076	81	(114,644)
Comprehensive income (loss)	$ 3,409,125	$ 921,050	$ 2,256,541	$ (1,290,518)
Net income (loss) per share of common stock:
Basic (in dollars per share)	$ 0.77	$ 0.17	$ 0.52	$ (0.28)
Diluted (in dollars per share)	$ 0.56	$ 0.15	$ 0.41	$ (0.28)
Weighted average shares outstanding used to compute net income (loss) per share:
Basic (in shares)	4,462,236	4,258,105	4,359,759	4,247,045
Diluted (in shares)	6,065,044	4,847,211	5,565,065	4,247,045

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2019		4,186,438
Beginning balance at Dec. 31, 2019	$ 34,416,026	$ 4,187	$ 97,239,455	$ (62,827,616)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		12,157
Exercise of stock options	90,000	$ 12	89,988
Exercise of warrants (in shares)		59,510
Exercise of warrants	595,101	$ 60	595,041
Stock based compensation	686,599		686,599
Net income (loss)	(1,684,643)			(1,684,643)
Foreign currency translation adjustment	(293,491)				(293,491)
Ending balance (in shares) at Mar. 31, 2020		4,258,105
Ending balance at Mar. 31, 2020	33,809,592	$ 4,259	98,611,083	(64,512,259)	(293,491)
Beginning balance (in shares) at Dec. 31, 2019		4,186,438
Beginning balance at Dec. 31, 2019	34,416,026	$ 4,187	97,239,455	(62,827,616)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(1,175,874)
Foreign currency translation adjustment	(114,644)
Ending balance (in shares) at Sep. 30, 2020		4,258,105
Ending balance at Sep. 30, 2020	35,541,117	$ 4,259	99,654,992	(64,003,490)	(114,644)
Beginning balance (in shares) at Mar. 31, 2020		4,258,105
Beginning balance at Mar. 31, 2020	33,809,592	$ 4,259	98,611,083	(64,512,259)	(293,491)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation	720,100		720,100
Net income (loss)	(216,205)			(216,205)
Foreign currency translation adjustment	(17,229)				(17,229)
Ending balance (in shares) at Jun. 30, 2020		4,258,105
Ending balance at Jun. 30, 2020	34,296,258	$ 4,259	99,331,183	(64,728,464)	(310,720)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation	323,809		323,809
Net income (loss)	724,974			724,974
Foreign currency translation adjustment	196,076				196,076
Ending balance (in shares) at Sep. 30, 2020		4,258,105
Ending balance at Sep. 30, 2020	35,541,117	$ 4,259	99,654,992	(64,003,490)	(114,644)
Beginning balance (in shares) at Dec. 31, 2020		4,258,105
Beginning balance at Dec. 31, 2020	35,492,242	$ 4,259	100,203,979	(64,689,065)	(26,931)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		65,962
Exercise of stock options	579,619	$ 66	579,553
Restricted stock issued (in shares)		6,527
Restricted stock issued	0	$ 6	(6)
Stock based compensation	745,620		745,620
Net income (loss)	(2,844,230)			(2,844,230)
Foreign currency translation adjustment	12,501				12,501
Ending balance (in shares) at Mar. 31, 2021		4,330,594
Ending balance at Mar. 31, 2021	33,985,752	$ 4,331	101,529,146	(67,533,295)	(14,430)
Beginning balance (in shares) at Dec. 31, 2020		4,258,105
Beginning balance at Dec. 31, 2020	$ 35,492,242	$ 4,259	100,203,979	(64,689,065)	(26,931)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	0
Net income (loss)	$ 2,256,460
Foreign currency translation adjustment	81
Ending balance (in shares) at Sep. 30, 2021		4,618,221
Ending balance at Sep. 30, 2021	42,005,357	$ 4,618	104,460,194	(62,432,605)	(26,850)
Beginning balance (in shares) at Mar. 31, 2021		4,330,594
Beginning balance at Mar. 31, 2021	33,985,752	$ 4,331	101,529,146	(67,533,295)	(14,430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		5,630
Exercise of stock options	36,605	$ 6	36,599
Restricted stock issued (in shares)		13,375
Restricted stock issued	0	$ 13	(13)
Stock based compensation	654,562		654,562
Net income (loss)	1,683,591			1,683,591
Foreign currency translation adjustment	(4,446)				(4,446)
Ending balance (in shares) at Jun. 30, 2021		4,349,599
Ending balance at Jun. 30, 2021	36,356,064	$ 4,350	102,220,294	(65,849,704)	(18,876)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		268,622
Exercise of stock options	1,545,834	$ 268	1,545,566
Stock based compensation	694,334		694,334
Net income (loss)	3,417,099			3,417,099
Foreign currency translation adjustment	(7,974)				(7,974)
Ending balance (in shares) at Sep. 30, 2021		4,618,221
Ending balance at Sep. 30, 2021	$ 42,005,357	$ 4,618	$ 104,460,194	$ (62,432,605)	$ (26,850)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net income (loss)	$ 2,256,460	$ (1,175,874)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	78,701	92,059
Amortization of debt discount	205,177	0
Non-cash lease expense	388,598	364,542
Stock based compensation	2,094,516	1,730,508
Change in assets and liabilities:
Accounts receivable	(6,514,964)	(1,394,991)
Prepaid and other current assets	860,631	(857,828)
Accounts payable and accrued expenses	(481,464)	1,235,607
Accrued salaries and wages	553,996	200,991
Lease liabilities	(392,564)	(363,363)
Royalty payable	1,228,605	331,495
Deferred revenue	(354,756)	(558,231)
Net cash used in operating activities	(77,064)	(395,085)
Cash flows from investing activities
Purchase of marketable securities	(15,044,750)	0
Purchase of property and equipment	0	(50,887)
Net cash used in investing activities	(15,044,750)	(50,887)
Cash flows provided by financing activities
Proceeds from stock option and warrant exercises	2,162,058	685,101
Net cash provided by financing activities	2,162,058	685,101
Effect of foreign currency translation on cash	(6,985)	(116,437)
Net increase (decrease) in cash and cash equivalents	(12,966,741)	122,692
Cash and cash equivalents, beginning of period	48,251,336	30,980,473
Cash and cash equivalents, end of period	35,284,595	31,103,165
Interest paid during the period	1,051,508	0
Income taxes paid during the period	0	39,000
Supplemental disclosure of non-cash finance transactions
Right of use assets obtained in exchange for new lease obligations	1,094,259	0
Issuance of restricted stock	19	0
Cashless exercise of options	$ 0	$ 2

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Company Opiant is a specialty pharmaceutical company developing medicines for addiction and drug overdose. The Company developed NARCAN® (naloxone hydrochloride) Nasal Spray (“NARCAN®”), a treatment to reverse opioid overdose. This product was conceived and developed by the Company, licensed to Adapt Pharma Operations Limited (“Adapt”), an Ireland based pharmaceutical company in December 2014 and approved by the U.S. Food and Drug Administration (“FDA”) in November 2015. In October 2018, Emergent BioSolutions, Inc. ("EBS") completed its acquisition of Adapt. The Company's current pipeline includes medicines in development for Opioid Overdose Reversal (“OOR”), Alcohol Use Disorder (“AUD”), Opioid Use Disorder (“OUD”), and Acute Cannabinoid Overdose (“ACO”). The Company is also pursuing other treatment opportunities within the addiction and drug overdose field. The Company has not had a bankruptcy, receivership or similar proceeding. The Company is required to comply with all regulations, rules and directives of governmental authorities and agencies applicable to the clinical testing and manufacturing and sale of pharmaceutical products.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the Company's financial position as of September 30, 2021 and December 31, 2020, results of operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited, a company incorporated on November 4, 2016 under the England and Wales Companies Act of 2006. Intercompany balances and transactions are eliminated upon consolidation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2020 included in the Company's Annual Report on Form 10-K filed with the SEC on March 4, 2021. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of: deferred income tax assets, equity instruments, stock-based compensation, acquired intangibles, and allowances for accounts receivable. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents were approximately $35.3 million and $48.3 million at September 30, 2021 and December 31, 2020, respectively. The Company maintains cash balances at financial institutions insured up to $250 thousand by the Federal Deposit Insurance Corporation. Balances in the UK are insured up to £85 thousand by the Financial Services Compensation Scheme (UK Equivalent). Although the Company’s cash balances exceeded these insured amounts at various times during the nine months ended September 30, 2021, the Company has not experienced any losses on its deposits of cash and cash equivalents for the periods presented. Earnings (Loss) Per Share Basic and diluted earnings (loss) per share is computed by dividing loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period. Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying condensed consolidated financial statements. Fully-diluted earnings (loss) per share is computed similarly to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). (in thousands, except per share data) For the Three Months Ended September 30, For the Nine Months Ended September 30, Numerator: 2021 2020 2021 2020 Net Income (loss) $ 3,417 $ 725 $ 2,256 $ (1,176) Denominator: Denominator for basic income (loss) per share - weighted average shares 4,462,236 4,258,105 4,359,759 4,247,045 Effect of dilutive securities: Equity incentive plans 1,602,808 589,106 1,205,306 — Denominator for diluted income (loss) per share 6,065,044 4,847,211 5,565,065 4,247,045 Income (loss) per share - Basic $ 0.77 0.17 $ 0.52 (0.28) Income (loss) per share - Diluted $ 0.56 0.15 $ 0.41 (0.28) The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive. For the Three Months Ended September 30, For the Nine Months Ended September 30, 2021 2020 2021 2020 Options to purchase common stock 295,550 729,692 407,975 3,077,692 Warrants to purchase common stock — 240,000 — 278,800 Unvested restricted stock — — 21,425 — Convertible Debt 509,165 — 509,165 — Total 804,715 969,692 938,565 3,356,492 Foreign Currency Translation The functional currency of the Company's wholly-owned subsidiary, Opiant UK is the British Pound, its local currency. Consequently, its assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of Opiant Pharmaceuticals UK Limited (“Opiant UK”), into U.S. dollars, the reporting currency, are excluded from the determination of net loss and are recorded in accumulated other comprehensive loss, a separate component of equity. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, ("FASB"), or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets    As of September 30, 2021, the Company had prepaid expenses and other current assets of approximately $2.1 million. The Company's prepaid expenses are primarily for advance research and development payments, insurance, software licenses, prepaid rent, and other amounts that relate to future periods of service. Other current assets primarily consist of such items as other receivables and security deposits.Other Non-Current AssetsAs of September 30, 2021 and December 31, 2020, the Company had non-current prepaid expenses of zero and approximately $1.1 million, respectively. The Company's non-current prepaid expenses are for advance research and development payments which will be issued for projects that have estimated completion dates of more than one year. As of September 30, 2021 all prepaid research and development expenses is classified as current as the services are expected to be provided prior to September 30, 2022.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities The Company invests in debt securities and has the intent and ability to hold until maturity. Therefore, the Company's Securities are classified as held-to-maturity. The Company's debt securities are all U.S. Treasury securities. The investments in debt securities are c arried at either amortized cost or fair value. As of September 30, 2021, the Company had a total of $15.0 million of tota l marketable securities, all invested in U.S. Treasury securities all of which is classified as a short term asset as the maturity is greater than three months, but less than one year. Any debt securities with original maturities of three months or less are classified as cash equivalents.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Accounts Receivable	Accounts Receivable    As of September 30, 2021 and December 31, 2020, the Company had accounts receivable of $15.4 million and $8.9 million respectively, which primarily relates to royalty revenue from sales of NARCAN®.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Leases On January 1, 2019, the Company adopted a new accounting standard, Topic 842, that amends the guidance for the accounting and reporting of leases. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Company's Condensed Consolidated Balance Sheets. The Company has entered into operating leases with terms greater than 12 months during the nine months ended September 30, 2021. In accordance with the guidance of Topic 842, the leases which are classified as operating leases are included in the Company's Condensed Consolidated Balance Sheets . The Company's operating leases do not include options to renew, do not contain residual value guarantees, do not have variable lease components, or impose significant restrictions or covenants. Right of use assets, "ROU assets", represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments over the respective lease term, with the ROU asset adjusted for deferred rent liability. The ROU asset is recognized as lease expense on a straight line basis over the lease term. As the implicit rate on the leases is not determinable, the Company uses judgement to estimate the incremental borrowing rate which is used as the discount rate to determine the present value of lease payments. The weighted average discount rate used was 8.8% and the weighted average remaining lease term is 4.45 years. The ROU asset and corresponding operating lease liability recognized at lease inception during the nine months ended September 30, 2021 was $1.09 million. The following table summarizes information related to the Company's operating leases and are included in the Company's Balance Sheet as of September 30, 2021. Balance Sheet descriptions September 30, 2021 Assets: (in thousands) Right of use assets - operating leases $ 998 Liabilities: Operating leases - current 287 Operating leases - long term 716 Total lease liabilities: $ 1,003 The following table summarizes the components of operating lease cost for the three and nine months ended September 30, 2021: Lease costs, (in thousands) Three months ended September 30, 2021 Nine months ended September 30, 2021 Operating expenses lease costs $ 112 $ 412 As of September 30, 2021, future minimum operating leases payments related to the Company’s operating lease liabilities were as follows: (in thousands) September 30, 2021 2021 (three months remaining) $ 118 2022 257 2023 236 2024 247 2025 276 2026 115 Total lease payments 1,249 Less imputed interest (246) Present value of operating lease liabilities $ 1,003

Other Non-Current Assets

Other Non-Current Assets	9 Months Ended
	Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Non-Current Assets	Prepaid Expenses and Other Current Assets    As of September 30, 2021, the Company had prepaid expenses and other current assets of approximately $2.1 million. The Company's prepaid expenses are primarily for advance research and development payments, insurance, software licenses, prepaid rent, and other amounts that relate to future periods of service. Other current assets primarily consist of such items as other receivables and security deposits.Other Non-Current AssetsAs of September 30, 2021 and December 31, 2020, the Company had non-current prepaid expenses of zero and approximately $1.1 million, respectively. The Company's non-current prepaid expenses are for advance research and development payments which will be issued for projects that have estimated completion dates of more than one year. As of September 30, 2021 all prepaid research and development expenses is classified as current as the services are expected to be provided prior to September 30, 2022.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Revenue	Revenue The Company's primary source of revenue is from royalty and milestone payments received from NARCAN® net sales by EBS. During the three and nine months ended September 30, 2021 the Company recorded revenue of $14.0 million and $27.7 million, respectively, related to its agreement with EBS. On September 19, 2018, the Company entered into a contract with the Biomedical Advanced Research and Development Authority (“BARDA”), which is part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to accelerate the Company’s development of OPTN003, its lead product candidate. OPTN003, nasal nalmefene, is a potent, long-acting opioid antagonist currently in development for the treatment of opioid overdose. The contract will provide potential funding up to a maximum of approximately $8.1 million and cover activities related to a planned new drug application ("NDA") submission for OPTN003 with the FDA. BARDA has awarded approximately $6.5 million of the contract through September 30, 2022, with the balance expected to be funded, subject to satisfactory project progress, availability of funds and certain other conditions. During the three and nine months ended September 30, 2021 the Company recognized revenue of $0.9 million and $3.3 million, respectively related to this contract. Deferred revenue On April 17, 2018, the Company was awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse, ("NIDA"). The grant provides the Company with additional resources for the ongoing development of OPNT003. The Company has been awarded the entire $7.4 million through the period ending March 31, 2022. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company recognized revenues from grants in the period during which the related costs were incurred, provided that the conditions under which the grants were provided had been met and only perfunctory obligations were outstanding. During the three and nine months ended September 30, 2021, the Company recognized revenue of $1.4 million and $3.0 million, respectively related to this grant. The following is a summary of the Company’s deferred revenue activity as of September 30, 2021: (in thousands) NIDA Grant Total Balance as of December 31, 2020 $ 355 $ 355 Additions to deferred revenue 2,187 2,187 Recognized as revenue (2,542) (2,542) Balance as of September 30, 2021 $ — $ —

Royalty Payable

Royalty Payable	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Royalty Payable	Royalty Payable    The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development of NARCAN®. In exchange for this funding, the Company agreed to provide investors with interest in the net profit generated from NARCAN® sales by EBS into perpetuity. As of September 30, 2021 and December 31, 2020, the Company recorded a royalty payable of $3.1 million and $1.9 million, respectively.

Long Term Debt

Long Term Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Long Term Debt	Long Term DebtAs of September 30, 2021 and December 31, 2020 the Company had long term debt of $18.9 million and $18.7 million, respectively. There have been no changes to the maturity or other conditions of the debt for the nine months ended September 30, 2021.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity Common Stock During the nine months ended September 30, 2021, the Company issued 340,214 shares of Common Stock as a result of stock option exercises, and received net cash proceeds of approximately $2.2 million. Stock Options On September 8, 2017, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”), at which time the 2017 Long-Term Incentive Plan ("2017 Plan") was approved by stockholder vote. The 2017 Plan allows the Company to grant both incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”) to purchase a maximum of 400,000 shares of the Company's Common Stock. Under the terms of the 2017 Plan, ISOs may only be granted to Company employees and directors, while NSOs may be granted to employees, directors, advisors, and consultants. The Company's Board of Directors (the "Board") has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value for an ISO or an NSO. The vesting period is normally over a period of four years, but can also be one year, from the grant date. The contractual term of an option is no longer than 10 years. The 2017 Plan also allows the Company to issue restricted stock units. As provided in the 2017 Plan, on January 1, 2021 the number of shares available for issuance was increased by 4% of the outstanding stock as of December 31, 2020, which represents an increase of 170,324 shares. As of September 30, 2021, the Company had 101,857 shares available for future issuance under the 2017 Plan. Prior to adopting the 2017 Plan, the Company did not have a formal long-term incentive stock plan. Prior to the implementation of the 2017 Plan, the Company had discretion to provide designated employees of the Company and its affiliates, certain consultants, and advisors who perform services for the Company and its affiliates, and non-employee members of the Board and its affiliates with the opportunity to receive grants of non-qualified stock options (the "Pre-2017 Non-Qualified Stock Options"). All of the Pre-2017 Non-Qualified Stock Option Grants were intended to qualify as non-qualified stock options. There were no Pre-2017 Non-Qualified Stock Option Grants that were intended to qualify as incentive stock options. Pre-2017 Non-Qualified Stock Options As of December 31, 2020, the Company had outstanding Pre-2017 Non-Qualified Stock Options to purchase, in the aggregate, 2,465,500 shares of the Company's Common Stock. During the nine months ended September 30, 2021, the Company did not grant any Pre-2017 Non-Qualified Stock Options. Stock option activity for the Pre-2017 Non-Qualified Stock Options for the nine months ended September 30, 2021 is presented in the table below: Number of Shares Weighted- average Exercise Price Weighted- average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 2,465,500 $ 6.99 4.09 $ 2,773,190 Exercised (337,693) 5.85 Forfeited (23,332) 10.00 Outstanding at September 30, 2021 2,104,475 $ 7.08 3.59 $ 39,269,107 A summary of the status of the Company’s non-vested Pre-2017 Non-Qualified Stock Options as of September 30, 2021 is presented below: Number of Options Weighted Average Grant Date Fair Value Vested at September 30, 2021 2,092,809 $ 7.06 Non-vested at September 30, 2021 11,666 $ 10.00 During the nine months ended September 30, 2021 and 2020, the Company recognized zero and $1 thousand, respectively, of non-cash expense related to Pre-2017 Non-Qualified Stock Options granted in prior periods. As of September 30, 2021, there was no further compensation expense to be recognized for the Pre-2017 Non-Qualified Stock Options. The 2017 Plan During the nine months ended September 30, 2021, the Company granted options to a number of employees to purchase 159,585 shares of the Company’s Common Stock at exercise prices from $8.20 to $16.41 per share, which represents the closing price of the Company’s Common Stock on the date of the grants. These options were issued under the Company’s 2017 Plan and have ten-year terms. Option grants to existing employees vest as follows: 1/48th of the option shares vest each month through the fourth anniversary of the grant date. Option grants to new employees vest as follows: 25% of the option shares vest on the one year anniversary of the grant date, and then 1/48th of the option shares vest on such date each month thereafter through the fourth anniversary of the grant date. The Company valued these options using the Black-Scholes option pricing model and estimated the aggregate fair value of the option grants to be $1.4 million. The assumptions used in the valuation of options granted under the 2017 Plan during the nine months ended September 30, 2021 were as follows: For the Nine Months Ended September 30, 2021 Market value of stock on measurement date $8.2 to $16.41 Risk-free interest rate 0.5% to 1.11% Dividend yield — Volatility factor 75.92% to 88.79% Term 5.50 to 6.25 years Stock option activity for options granted under the 2017 Plan during the nine months ended September 30, 2021 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance at December 31, 2020 611,760 $ 21.39 7.85 $ — Granted 159,585 $ 12.11 Exercised (2,521) $ 9.03 Forfeited (6,044) $ 11.38 Balance at September 30, 2021 762,780 $ 19.53 7.57 $ 6,307,064 A summary of the status of the Company’s vested and non-vested options granted under the 2017 Plan as of September 30, 2021 is presented in the following table: Number of Shares Weighted Average Grant Date Fair Value Per Share Vested at September 30, 2021 481,750 22.31 Non-vested at September 30, 2021 281,030 $ 10.29 During the nine months ended September 30, 2021 and 2020, the Company recognized approximately $1.4 million and $1.6 million, respectively of non-cash expense related to options granted under the 2017 Plan. As of September 30, 2021, there was approximately $1.3 million of unrecognized compensation costs related to non-vested stock options that were granted under the 2017 Plan. Restricted Stock Activity The following summarizes the restricted stock activity under the Company's 2017 Plan during the nine months ended September 30, 2021: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2020 49,600 $ 12.00 Restricted stock granted 76,268 $ 12.47 Restricted stock vested (19,902) $ 10.79 Restricted stock outstanding and unvested at September 30, 2021 105,966 $ 12.57 Twenty-five percent (25%) of the restricted stock units will vest on the one year anniversary of the vesting commencement date, and twenty-five percent (25%) will vest annually thereafter on the same day as the vesting commencement date. During the nine months ended September 30, 2021, the Company recognized approximately $563 thousand of non-cash expense related to restricted stock units. As of September 30, 2021, there was $0.7 million of total unrecognized compensation cost related to restricted stock units. Inducement Equity Incentive Plan On July 8, 2021, the Board of Directors of the Company adopted the 2021 Inducement Equity Incentive Plan (the “Inducement Plan”) and, subject to the adjustment provisions of the Inducement Plan, reserved 100,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. During July 2021 the Company issued options to purchase 56,500 shares of common stock, and restricted stock units for 18,200 shares of common stock under the Inducement Plan. The assumptions used in the valuation of options granted under the Inducement Plan during the nine months ended September 30, 2021 were as follows: For the Nine Months Ended September 30, 2021 Market value of stock on measurement date $ 16.41 Risk-free interest rate 0.84 % Dividend yield — Volatility factor 76.26 % Term 6.25 years Stock option activity for options granted under the Inducement Plan during the nine months ended September 30, 2021 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance at December 31, 2020 — Granted 56,500 $ 16.41 Exercised — Forfeited — Balance at September 30, 2021 56,500 $ 16.41 9.8 $ 527,145 During the three months ended September 30, 2021, the Company recognized approximately $91 thousand of non-cash expense related to options granted under the Inducement Plan. As of September 30, 2021, there was approximately $0.5 million of total unrecognized compensation cost related to the non-vested stock options that were granted under the 2021 Inducement Equity Incentive Plan. The following summarizes the restricted stock activity under the Inducement Plan during the nine months ended September 30, 2021: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2020 — Restricted stock granted 18,200 $ 16.41 Restricted stock vested Restricted stock outstanding and unvested at September 30, 2021 18,200 $ 16.41 During the three months ended September 30, 2021, the Company recognized approximately $39 thousand of non-cash expense related to restricted stock units. As of September 30, 2021, there was approximately $260 thousand of total unrecognized compensation cost related to restricted stock units. Warrants During the nine months ended September 30, 2021, the Company did not issue any warrants. Warrant activity for the nine months ended September 30, 2021 is presented in the table below: Number of Shares Weighted- average Exercise Price Weighted- average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 278,800 $ 9.72 3.51 $ 1,164,000 Exercised — $ — Forfeited — $ — Outstanding at September 30, 2021 278,800 $ 9.72 2.76 $ 4,465,912 Exercisable at September 30, 2021 278,800 $ 9.72 2.76 $ 4,465,912

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments The Company has entered into various agreements related to its business activities. The following is a summary of the Company’s commitments: Aptar Agreement On October 26, 2020, the Company entered into a Master Services Agreement (“MSA”) with AptarGroup, Inc. (“Aptar”) to provide non-exclusive technology access and co-development services for the development and submission of an opioid antagonist for the treatment of opioid overdose using Aptar’s nasal Unidose device (the “UDS Device”). In addition to the cost of the UDS Devices, the Company expects to spend up to approximately $5.2 million over the course of the development program. Summit Agreement On July 22, 2020, the Company the Company entered into a Project Scope Agreement ("PSA") pursuant to a Master Services Agreement ("MSA") with Summit Biosciences, Inc. ("Summit"), to support the development and manufacture of a nasal spray device for opioid overdose, with the ability to expand to additional programs in the future. In accordance with the PSA, Summit will develop and produce certain pre-filled nasal spray products using a device previously evaluated as part of other FDA-approved nasal spray products. The Company will pay Summit estimated costs and fees up to approximately $7.5 million of which a deposit of approximately $1.1 million was paid as of September 30, 2021, which is included in current assets in the condensed consolidated balance sheet. Torreya Agreement The Company entered into a consulting agreement with Torreya Partners LLP ("Torreya"), a financial advisory firm, under which Torreya agreed to provide certain financial advisory services. The Company is required to pay fees equivalent to 3.375% of all amounts received by the Company from net sales of NARCAN® into perpetuity. During the nine months ended September 30, 2021 and 2020, the Company recorded $935 thousand and $643 thousand, respectively of expense related to the agreement with Torreya. Exclusive License and Collaboration Agreement On November 19, 2015, the Company entered into an exclusive license agreement and collaboration agreement (“LOI”) with a pharmaceutical company with certain desirable proprietary information. Pursuant to the agreement, the Company is obligated to issue shares of unregistered Common Stock upon the occurrence of various milestones. No shares were required to be issued under this agreement during the nine months ended September 30, 2021 and 2020. Supply Agreement On June 22, 2017, the Company entered into a license agreement (the "License Agreement") and a related supply agreement (the “Supply Agreement”) with Aegis Therapeutics LLC, acquired by Neurelis, Inc. in 2018, (the combined entity hereafter, "Neurelis", pursuant to which the Company was granted an exclusive license (the “License”) to Neurelis’ proprietary chemically synthesizable delivery enhancement and stabilization agents, including, but not limited to, Neurelis’ Intravail® absorption enhancement agents, ProTek® and HydroGel® (collectively, the “Technology”) to exploit (a) the Compounds (as such are defined in the License Agreement) and (b) a product containing a Compound and formulated using the Technology (“Product”), in each case of (a) and (b) for any and all purposes. The License Agreement restricts the Company's ability to manufacture any Aegis excipients included in the Technology (“Excipients”), except for certain instances of supply failure, supply shortage or termination of the Supply Agreement, and the Company shall obtain all supply of such Excipients from Neurelis under the Supply Agreement. The License Agreement also restricts Neurelis’s ability to compete with the Company worldwide with respect to the Exploitation (as defined in the License Agreement) of any therapeutic containing a Compound or derivative or active metabolite of a Compound without the Company's prior written consent. The effective date of the License Agreement and the Supply Agreement is January 1, 2017. As consideration for the grant of the License, the Company paid Neurelis two immaterial upfront payments, of which the Company paid 50% by issuing the Company's Common Stock to Neurelis with the number of shares issued equal to 75% of the average closing price of the Company's Common Stock over the 20 trading days preceding the date of payment. The License Agreement also provides for (A) additional developmental milestone payments for each Product containing a different Compound equal to up to an aggregate of $1.8 million, (B) additional commercialization milestone payments for each Product containing a different Compound equal to up to an aggregate of $5.0 million, and (C) single low digit royalties on the Annual Net Sales (as defined in the License Agreement) of all Products during the Royalty Term (as defined in the License Agreement) according to a tiered royalty rate based on Annual Net Sales of the Products by the Company, the Company's sublicensees and affiliates. The Company shall also pay to Neurelis a sublicense fee based on a sublicense rate negotiated in good faith by the parties. The License Agreement contains customary representations and warranties, ownership, patent rights, confidentiality, indemnification and insurance provisions. The License Agreement shall expire upon the expiration of the Company's obligation to pay royalties under such License Agreement; provided, however, that the Company shall have the right to terminate the License granted on a Product-by-Product or country-by-country basis upon 30 days’ prior written notice to Neurelis. Under the terms of the Supply Agreement, Neurelis shall deliver to the Company any preclinical, clinical and commercial supply of the Excipients, which Aegis sources from various contract manufacturers. The Supply Agreement has a term of 20 years but shall terminate automatically in the event of expiration or termination of the License Agreement or at any time upon the written agreement of both parties. The Supply Agreement contains customary provisions relating to pricing for such materials, forecasts, delivery, inspection, indemnification, insurance and representations, warranties and covenants. The Supply Agreement includes technology transfer provisions for the transfer of all materials and know-how specific to the manufacturing of the Excipients that is necessary or useful for the Company to manufacture such Excipients. The Company does not have the right to manufacture such Excipients except in the event that Neurelis is unable to supply and sell any portion of the material to the Company (subject to a 60-day cure period). Under the License Agreement, the Company will be required to pay Neurelis $250 thousand upon the successful NDA filing. For the nine months ended September 30, 2021, and 2020 the Company did not have any expenses associated with the License Agreement. Contingencies The Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss will be incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. If any legal matter, were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s would reflect any potential claim in the consolidated financial statements for that reporting period. The Company and Emergent BioSolutions Inc., through its Adapt Pharma subsidiaries (collectively, “Plaintiffs”), filed complaints, in 2016 against Teva Pharmaceuticals Industries Ltd. (“Teva”), and in 2018 against Perrigo UK FINCO Limited Partnership (“Perrigo”), relating to Teva’s and Perrigo’s respective abbreviated new drug applications (each, an “ANDA”) seeking to market generic versions of NARCAN® (naloxone hydrochloride) Nasal Spray 4mg/spray. On February 12, 2020, Plaintiffs and Perrigo entered into a settlement agreement to resolve the ongoing litigation. Under the terms of the settlement, Perrigo has received a non-exclusive license under the Company's patents licensed to Adapt to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo’s license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva or litigation against future ANDA filers. The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey. Closing arguments in the Teva trial were held on February 26, 2020. Plaintiffs also filed a complaint related to Teva’s ANDA seeking to market a generic version of NARCAN® (naloxone hydrochloride) Nasal Spray 2mg/spray. On June 5, 2020, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of Teva. The Company's commercial partner Emergent BioSolutions, Inc., has appealed the decision to the Court of Appeals for the Federal Circuit. On August 2, 2021, a panel consisting of three appeals-court judges held a hearing on EBS’s appeal of the New Jersey District Court’s decision. A decision by the Court of Appeals is expected in the fourth quarter of 2021 or early 2022.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events During October 2021, 17,064 shares of common stock subject to outstanding options were exercised, and the Company received net cash proceeds of approximately $95,000. During October 2021, the Company issued options to purchase 3,700 shares of common stock under the 2017 Plan. During October 2021, Pontifax Medisen Finance ("Pontifax") voluntarily converted approximately $1.7 million of the outstanding $10.0 million convertible debt held by Pontifax into a total of 85,000 shares of common stock at a conversion rate of $19.64 per share.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the Company's financial position as of September 30, 2021 and December 31, 2020, results of operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the three and nine months ended September 30, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited, a company incorporated on November 4, 2016 under the England and Wales Companies Act of 2006. Intercompany balances and transactions are eliminated upon consolidation. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2020 included in the Company's Annual Report on Form 10-K filed with the SEC on March 4, 2021.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of: deferred income tax assets, equity instruments, stock-based compensation, acquired intangibles, and allowances for accounts receivable.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents were approximately $35.3 million and $48.3 million at September 30, 2021 and December 31, 2020, respectively. The Company maintains cash balances at financial institutions insured up to $250 thousand by the Federal Deposit Insurance Corporation. Balances in the UK are insured up to £85 thousand by the Financial Services Compensation Scheme (UK Equivalent). Although the Company’s cash balances exceeded these insured amounts at various times during the nine months ended September 30, 2021, the Company has not experienced any losses on its deposits of cash and cash equivalents for the periods presented.
Earnings (Loss) Per Share	Basic and diluted earnings (loss) per share is computed by dividing loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period.
Foreign Currency Translations	The functional currency of the Company's wholly-owned subsidiary, Opiant UK is the British Pound, its local currency. Consequently, its assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of Opiant Pharmaceuticals UK Limited (“Opiant UK”), into U.S. dollars, the reporting currency, are excluded from the determination of net loss and are recorded in accumulated other comprehensive loss, a separate component of equity. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.
Recently Adopted Accounting Pronouncements	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, ("FASB"), or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.    The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Earnings (Loss) Per Share, Basic and Diluted	Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying condensed consolidated financial statements. Fully-diluted earnings (loss) per share is computed similarly to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). (in thousands, except per share data) For the Three Months Ended September 30, For the Nine Months Ended September 30, Numerator: 2021 2020 2021 2020 Net Income (loss) $ 3,417 $ 725 $ 2,256 $ (1,176) Denominator: Denominator for basic income (loss) per share - weighted average shares 4,462,236 4,258,105 4,359,759 4,247,045 Effect of dilutive securities: Equity incentive plans 1,602,808 589,106 1,205,306 — Denominator for diluted income (loss) per share 6,065,044 4,847,211 5,565,065 4,247,045 Income (loss) per share - Basic $ 0.77 0.17 $ 0.52 (0.28) Income (loss) per share - Diluted $ 0.56 0.15 $ 0.41 (0.28)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive. For the Three Months Ended September 30, For the Nine Months Ended September 30, 2021 2020 2021 2020 Options to purchase common stock 295,550 729,692 407,975 3,077,692 Warrants to purchase common stock — 240,000 — 278,800 Unvested restricted stock — — 21,425 — Convertible Debt 509,165 — 509,165 — Total 804,715 969,692 938,565 3,356,492

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Summary of Operating Leases	The following table summarizes information related to the Company's operating leases and are included in the Company's Balance Sheet as of September 30, 2021. Balance Sheet descriptions September 30, 2021 Assets: (in thousands) Right of use assets - operating leases $ 998 Liabilities: Operating leases - current 287 Operating leases - long term 716 Total lease liabilities: $ 1,003
Summary of Components of Operating Lease Cost	The following table summarizes the components of operating lease cost for the three and nine months ended September 30, 2021: Lease costs, (in thousands) Three months ended September 30, 2021 Nine months ended September 30, 2021 Operating expenses lease costs $ 112 $ 412
Maturity of Operating Lease Liabilities	As of September 30, 2021, future minimum operating leases payments related to the Company’s operating lease liabilities were as follows: (in thousands) September 30, 2021 2021 (three months remaining) $ 118 2022 257 2023 236 2024 247 2025 276 2026 115 Total lease payments 1,249 Less imputed interest (246) Present value of operating lease liabilities $ 1,003

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Schedule of Deferred Revenue Activity	The following is a summary of the Company’s deferred revenue activity as of September 30, 2021: (in thousands) NIDA Grant Total Balance as of December 31, 2020 $ 355 $ 355 Additions to deferred revenue 2,187 2,187 Recognized as revenue (2,542) (2,542) Balance as of September 30, 2021 $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	Stock option activity for the Pre-2017 Non-Qualified Stock Options for the nine months ended September 30, 2021 is presented in the table below: Number of Shares Weighted- average Exercise Price Weighted- average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 2,465,500 $ 6.99 4.09 $ 2,773,190 Exercised (337,693) 5.85 Forfeited (23,332) 10.00 Outstanding at September 30, 2021 2,104,475 $ 7.08 3.59 $ 39,269,107 Stock option activity for options granted under the 2017 Plan during the nine months ended September 30, 2021 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance at December 31, 2020 611,760 $ 21.39 7.85 $ — Granted 159,585 $ 12.11 Exercised (2,521) $ 9.03 Forfeited (6,044) $ 11.38 Balance at September 30, 2021 762,780 $ 19.53 7.57 $ 6,307,064 Stock option activity for options granted under the Inducement Plan during the nine months ended September 30, 2021 is presented in the table below: Number of Options Outstanding Weighted-average Exercise Price Weighted-average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance at December 31, 2020 — Granted 56,500 $ 16.41 Exercised — Forfeited — Balance at September 30, 2021 56,500 $ 16.41 9.8 $ 527,145 Warrant activity for the nine months ended September 30, 2021 is presented in the table below: Number of Shares Weighted- average Exercise Price Weighted- average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 278,800 $ 9.72 3.51 $ 1,164,000 Exercised — $ — Forfeited — $ — Outstanding at September 30, 2021 278,800 $ 9.72 2.76 $ 4,465,912 Exercisable at September 30, 2021 278,800 $ 9.72 2.76 $ 4,465,912
Schedule of Nonvested Share Activity	A summary of the status of the Company’s non-vested Pre-2017 Non-Qualified Stock Options as of September 30, 2021 is presented below: Number of Options Weighted Average Grant Date Fair Value Vested at September 30, 2021 2,092,809 $ 7.06 Non-vested at September 30, 2021 11,666 $ 10.00 A summary of the status of the Company’s vested and non-vested options granted under the 2017 Plan as of September 30, 2021 is presented in the following table: Number of Shares Weighted Average Grant Date Fair Value Per Share Vested at September 30, 2021 481,750 22.31 Non-vested at September 30, 2021 281,030 $ 10.29
Schedule of Assumptions Used in the Valuation	The assumptions used in the valuation of options granted under the 2017 Plan during the nine months ended September 30, 2021 were as follows: For the Nine Months Ended September 30, 2021 Market value of stock on measurement date $8.2 to $16.41 Risk-free interest rate 0.5% to 1.11% Dividend yield — Volatility factor 75.92% to 88.79% Term 5.50 to 6.25 years The assumptions used in the valuation of options granted under the Inducement Plan during the nine months ended September 30, 2021 were as follows: For the Nine Months Ended September 30, 2021 Market value of stock on measurement date $ 16.41 Risk-free interest rate 0.84 % Dividend yield — Volatility factor 76.26 % Term 6.25 years
Restricted Stock Activity	The following summarizes the restricted stock activity under the Company's 2017 Plan during the nine months ended September 30, 2021: Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2020 49,600 $ 12.00 Restricted stock granted 76,268 $ 12.47 Restricted stock vested (19,902) $ 10.79 Restricted stock outstanding and unvested at September 30, 2021 105,966 $ 12.57 Number of Shares Weighted Average Fair Value Per Share Restricted stock outstanding and unvested at December 31, 2020 — Restricted stock granted 18,200 $ 16.41 Restricted stock vested Restricted stock outstanding and unvested at September 30, 2021 18,200 $ 16.41

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)	Sep. 30, 2021USD ($)	Sep. 30, 2021GBP (£)	Dec. 31, 2020USD ($)
Accounting Policies [Abstract]
Cash and cash equivalents	$ 35,284,595		$ 48,251,336
FDIC insured amount	$ 250,000
FSCS insured amount | £		£ 85,000

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Earnings (Loss) Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Accounting Policies [Abstract]
Net income (loss)	$ 3,417,099	$ 1,683,591	$ (2,844,230)	$ 724,974	$ (216,205)	$ (1,684,643)	$ 2,256,460	$ (1,175,874)
Denominator for basic income (loss) per share - weighted-average shares (in shares)	4,462,236			4,258,105			4,359,759	4,247,045
Equity incentive plans (in shares)	1,602,808			589,106			1,205,306	0
Denominator for diluted income (loss) per share (in shares)	6,065,044			4,847,211			5,565,065	4,247,045
Income (loss) per share - Basic (in dollars per share)	$ 0.77			$ 0.17			$ 0.52	$ (0.28)
Income (loss) per share - Diluted (in dollars per share)	$ 0.56			$ 0.15			$ 0.41	$ (0.28)

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	804,715	969,692	938,565	3,356,492
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	295,550	729,692	407,975	3,077,692
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	0	240,000	0	278,800
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	0	0	21,425	0
Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in shares)	509,165	0	509,165	0

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid and other current assets	$ 2,121,145	$ 1,936,842

Marketable Securities (Details)

Marketable Securities (Details) $ in Millions	Sep. 30, 2021USD ($)
Investments, Debt and Equity Securities [Abstract]
Marketable securities	$ 15

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 15,425,938	$ 8,910,975
Royalty revenue from sales of NARCAN
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 15,400,000	$ 8,900,000

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Jan. 01, 2019
Leases [Abstract]
Operating lease, weighted average discount rate, percent	8.80%
Operating lease, weighted average remaining lease term	4 years 5 months 12 days
Right of use assets - operating leases	$ 997,777	$ 278,455	$ 1,090,000
Total lease liabilities:	$ 1,003,000		$ 1,090,000

Leases - Balance Sheet Descript

Leases - Balance Sheet Descriptions of Operating Leases (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Jan. 01, 2019
Assets:
Right of use assets - operating leases	$ 997,777	$ 278,455	$ 1,090,000
Liabilities:
Operating leases - current	287,139	282,421
Operating leases - long term	716,343	$ 0
Total lease liabilities:	$ 1,003,000		$ 1,090,000

Leases - Components of Operatin

Leases - Components of Operating Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Leases [Abstract]
Operating expenses lease costs	$ 112	$ 412

Leases - Maturity of Operating

Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jan. 01, 2019
Leases [Abstract]
2021 (three months remaining)	$ 118
2022	257
2023	236
2024	247
2025	276
2026	115
Total lease payments	1,249
Less imputed interest	(246)
Present value of operating lease liabilities	$ 1,003	$ 1,090

Other Non-Current Assets - Narr

Other Non-Current Assets - Narrative (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other non-current assets	$ 0	$ 1,100,000

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	Sep. 19, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2022	Sep. 30, 2022	Apr. 17, 2018
Deferred Revenue Arrangement [Line Items]
Revenue		$ 14,041,006	$ 8,600,811	$ 27,688,713	$ 19,056,999
Grants receivable								$ 7,400,000
Research and development arrangement september 19, 2018
Deferred Revenue Arrangement [Line Items]
Revenue		900,000		3,300,000
Plan | BARDA
Deferred Revenue Arrangement [Line Items]
Proceeds from funding agreement	$ 8,100,000
Forecast | BARDA
Deferred Revenue Arrangement [Line Items]
Proceeds from funding agreement							$ 6,500,000
Grant
Deferred Revenue Arrangement [Line Items]
Revenue		$ 1,400,000		$ 3,000,000
Grant | Forecast
Deferred Revenue Arrangement [Line Items]
Revenue						$ 7,400,000

Revenue - Summary of Deferred R

Revenue - Summary of Deferred Revenue Activity (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period	$ 355
Additions to deferred revenue	2,187
Recognized as revenue	(2,542)
Balance at end of period	0
NIDA Grant
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period	355
Additions to deferred revenue	2,187
Recognized as revenue	(2,542)
Balance at end of period	$ 0

Royalty Payable - Narrative (De

Royalty Payable - Narrative (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Royalty payable	$ 3,136,677	$ 1,908,072

Long Term Debt (Details)

Long Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Long-term debt	$ 18.9	$ 18.7

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from stock option and warrant exercises	$ 2,162,058	$ 685,101
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)	340,214

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options (Details) - 2017 Plan - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Jan. 01, 2021	Sep. 08, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)				400,000
Expiration period	10 years
Percentage increase of authorized shares			4.00%
Annual additional options authorized (in shares)	101,857	170,324
Options to purchase common stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Options to purchase common stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year

Stockholders' Equity - Pre-2017

Stockholders' Equity - Pre-2017 Non-Qualified Stock Options, Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	56,500	56,500		0
Options granted (in shares)		56,500
Stock based compensation expense		$ 563,000
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 91,000
Pre-2017 non-qualified stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	2,104,475	2,104,475		2,465,500
Options granted (in shares)		0
Pre-2017 non-qualified stock options | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense		$ 0	$ 1,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Pre-2017 Non-Qualified Stock Options Outstanding (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding at end of period (in shares)	56,500	0
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares
Exercised (in dollars per share) | $ / shares
Outstanding at end of period (in dollars per share) | $ / shares	$ 16.41
Weighted- average Remaining Contractual Term (years)
Outstanding	9 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding | $	$ 527,145
Pre-2017 non-qualified stock options
Number of Shares
Outstanding at beginning of period (in shares)	2,465,500
Exercised (in shares)	(337,693)
Forfeited (in shares)	(23,332)
Outstanding at end of period (in shares)	2,104,475	2,465,500
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 6.99
Exercised (in dollars per share) | $ / shares	5.85
Forfeited (in dollars per share) | $ / shares	10
Outstanding at end of period (in dollars per share) | $ / shares	$ 7.08	$ 6.99
Weighted- average Remaining Contractual Term (years)
Outstanding	3 years 7 months 2 days	4 years 1 month 2 days
Aggregate Intrinsic Value
Outstanding | $	$ 39,269,107	$ 2,773,190

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Pre-2017 Non-Qualified Stock Options Nonvested Share Activity (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of Options
Vested (in shares) | shares	481,750
Weighted Average Grant Date Fair Value Per Share
Vested (in dollars per share) | $ / shares	$ 22.31
Pre-2017 non-qualified stock options
Number of Options
Vested (in shares) | shares	2,092,809
Non-vested (in shares) | shares	11,666
Weighted Average Grant Date Fair Value Per Share
Vested (in dollars per share) | $ / shares	$ 7.06
Non-vested (in dollars per share) | $ / shares	$ 10

Stockholders' Equity - The 2017

Stockholders' Equity - The 2017 Plan, Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)		56,500
Options granted, exercise price (in dollars per share)		$ 16.41
Stock based compensation expense		$ 563
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 91
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)		159,585
Options granted, exercise price (in dollars per share)		$ 12.11
Expiration period		10 years
Fair value of option granted		$ 1,400
Compensation not yet recognized	$ 1,300	$ 1,300
2017 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, exercise price (in dollars per share)		$ 8.20
2017 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, exercise price (in dollars per share)		$ 16.41
2017 Plan | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		10 years
Stock based compensation expense		$ 1,400	$ 1,600
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Tranche One | 2017 Plan | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Tranche Two | 2017 Plan | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		2.0833%
Tranche Three | 2017 Plan | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		2.0833%
Tranche Four | 2017 Plan | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		2.0833%

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of 2017 Plan Valuation Assumptions (Details) - Options to purchase common stock - 2017 Plan	9 Months Ended
	Sep. 30, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 16.41
Risk-free interest rate	0.84%
Dividend yield	0.00%
Volatility factor	76.26%
Term	6 years 3 months
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 8.2
Risk-free interest rate	0.50%
Volatility factor	75.92%
Term	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 16.41
Risk-free interest rate	1.11%
Volatility factor	88.79%
Term	6 years 3 months

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of 2017 Plan Options Outstanding (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Number of Options Outstanding
Outstanding at beginning of period (in shares) | shares	0
Granted (in shares) | shares	56,500
Exercised (in shares) | shares	0
Forfeited (in shares) | shares	0
Outstanding at end of period (in shares) | shares	56,500	0
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares
Granted (in dollars per share) | $ / shares	16.41
Exercised (in dollars per share) | $ / shares
Forfeited (in dollars per share) | $ / shares
Outstanding at end of period (in dollars per share) | $ / shares	$ 16.41
Weighted- average Remaining Contractual Term (years)
Outstanding	9 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding | $	$ 527,145
2017 Plan
Number of Options Outstanding
Outstanding at beginning of period (in shares) | shares	611,760
Granted (in shares) | shares	159,585
Exercised (in shares) | shares	(2,521)
Forfeited (in shares) | shares	(6,044)
Outstanding at end of period (in shares) | shares	762,780	611,760
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 21.39
Granted (in dollars per share) | $ / shares	12.11
Exercised (in dollars per share) | $ / shares	9.03
Forfeited (in dollars per share) | $ / shares	11.38
Outstanding at end of period (in dollars per share) | $ / shares	$ 19.53	$ 21.39
Weighted- average Remaining Contractual Term (years)
Outstanding	7 years 6 months 25 days	7 years 10 months 6 days
Aggregate Intrinsic Value
Outstanding | $	$ 6,307,064	$ 0

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of 2017 Nonvested Share Activity (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of Shares
Vested (in shares) | shares	481,750
Weighted Average Grant Date Fair Value Per Share
Vested (in dollars per share) | $ / shares	$ 22.31
2017 Plan
Number of Shares
Non-vested, ending balance (in shares) | shares	281,030
Weighted Average Grant Date Fair Value Per Share
Non-vested, ending balance (in dollars per share) | $ / shares	$ 10.29

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Restricted Stock Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares) | shares		49,600
Granted (in shares) | shares		76,268
Vested (in shares) | shares		(19,902)
Outstanding at end of period (in shares) | shares	105,966	105,966
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares		$ 12
Granted (in dollars per share) | $ / shares		12.47
Vested (in dollars per share) | $ / shares		10.79
Outstanding at end of period (in dollars per share) | $ / shares	$ 12.57	$ 12.57
Stock based compensation expense | $		$ 563
Compensation cost not yet recognized | $	$ 700	$ 700
Unvested restricted stock
Number of Shares
Outstanding at beginning of period (in shares) | shares		0
Granted (in shares) | shares		18,200
Vested (in shares) | shares
Outstanding at end of period (in shares) | shares	18,200	18,200
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share) | $ / shares
Granted (in dollars per share) | $ / shares		16.41
Vested (in dollars per share) | $ / shares
Outstanding at end of period (in dollars per share) | $ / shares	$ 16.41	$ 16.41
Stock based compensation expense | $	$ 39
Compensation cost not yet recognized | $	$ 260	$ 260

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021
Number of Shares
Outstanding at beginning of period (in shares)	49,600
Granted (in shares)	76,268
Vested (in shares)	(19,902)
Outstanding at end of period (in shares)	105,966
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 12
Granted (in dollars per share)	12.47
Vested (in dollars per share)	10.79
Outstanding at end of period (in dollars per share)	$ 12.57
Stock based compensation expense	$ 563
Compensation cost not yet recognized	$ 700
Tranche One
Weighted Average Fair Value Per Share
Vesting percentage	25.00%
Tranche Two
Weighted Average Fair Value Per Share
Vesting percentage	25.00%

Stockholder's Equity- Inducemen

Stockholder's Equity- Inducement Equity Incentive Plan (Details) - shares	1 Months Ended	9 Months Ended
	Jul. 31, 2021	Sep. 30, 2021	Jul. 08, 2021
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)		340,214
Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)			100,000
Inducement Equity Incentive Plan | Unvested restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)	18,200
Inducement Equity Incentive Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)	56,500

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of 2017 Plan Valuation of Options Granted (Details) - Options to purchase common stock - 2017 Plan	9 Months Ended
	Sep. 30, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 16.41
Risk-free interest rate	0.84%
Dividend yield	0.00%
Volatility factor	76.26%
Term	6 years 3 months

Stockholders' Equity - Stock _2

Stockholders' Equity - Stock Option Activity for Option Granted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Number of Shares
Outstanding at beginning of period (in shares)		0
Options granted (in shares)		56,500
Exercised (in shares)		0
Forfeited (in shares)		0
Outstanding at end of period (in shares)	56,500	56,500	0
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share)
Options granted, exercise price (in dollars per share)		16.41
Exercised (in dollars per share)
Forfeited (in dollars per share)
Outstanding at end of period (in dollars per share)	$ 16.41	$ 16.41
Weighted- average Remaining Contractual Term (years)
Outstanding		9 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding	$ 527,145	$ 527,145
Compensation cost not yet recognized	700	700
Stock based compensation expense		563
Options to purchase common stock
Aggregate Intrinsic Value
Compensation cost not yet recognized	500	$ 500
Stock based compensation expense	$ 91

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants, Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Sep. 30, 2021
Class of Warrant or Right [Line Items]
Warrants issued	$ 595,101
Warrants to purchase common stock
Class of Warrant or Right [Line Items]
Warrants issued		$ 0

Stockholders' Equity - Schedu_8

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Number of Shares
Outstanding at beginning of period (in shares)	49,600
Outstanding at end of period (in shares)	105,966	49,600
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 12
Outstanding at end of period (in dollars per share)	$ 12.57	$ 12
Warrants to purchase common stock
Number of Shares
Outstanding at beginning of period (in shares)	278,800
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding at end of period (in shares)	278,800	278,800
Exercisable (in shares)	278,800
Weighted Average Fair Value Per Share
Outstanding at beginning of period (in dollars per share)	$ 9.72
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding at end of period (in dollars per share)	9.72	$ 9.72
Exercisable (in dollars per share)	$ 9.72
Weighted- average Remaining Contractual Term (years)
Outstanding	2 years 9 months 3 days	3 years 6 months 3 days
Exercisable weighted average remaining contractual terms	2 years 9 months 3 days
Aggregate Intrinsic Value
Outstanding	$ 4,465,912	$ 1,164
Exercisable aggregate intrinsic value	$ 4,465,912

Commitment and Contingencies -

Commitment and Contingencies - Aptar Agreement (Details) $ in Millions	Oct. 26, 2020USD ($)
AptarGroup, Inc.
Other Commitments [Line Items]
Development costs	$ 5.2

Commitments and Contingencies -

Commitments and Contingencies - Summit Agreement (Details) - Summit BioScience, Inc. - USD ($) $ in Millions	Jul. 22, 2020	Sep. 30, 2021
Other Commitments [Line Items]
Estimated fees and cost (up to)	$ 7.5
Payment for deposit		$ 1.1

Commitments and Contingencies_2

Commitments and Contingencies - Torreya Agreement (Details) - Advisory services - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Other Commitments [Line Items]
Additional consultant fee payable, percentage of perpetuity	3.375%
Sponsor fees	$ 935	$ 643

Commitments and Contingencies_3

Commitments and Contingencies - Exclusive License and Collaboration Agreement (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Letter of intent
Other Commitments [Line Items]
Stock newly-issued during the period (in shares)	0	0

Commitments and Contingencies_4

Commitments and Contingencies - Supply Agreement (Details) $ in Thousands	Jun. 22, 2017USD ($)paymentday	Sep. 30, 2021USD ($)
License agreement
Other Commitments [Line Items]
Upfront payments | payment	2
Percent of upfront payments which may be paid by issuing common stock	50.00%
Percent of average share price	75.00%
Threshold trading days | day	20
Maximum additional product milestone payments	$ 1,800
Maximum additional commercialization milestone payments	$ 5,000
Termination advance notice period	30 days
Other commitment		$ 250
Supply agreement
Other Commitments [Line Items]
Other commitment, period	20 years
Material cure period	60 days

Subsequent Events - Narrative (

Subsequent Events - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended				9 Months Ended
	Oct. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2021
Subsequent Event [Line Items]
Exercise of stock options (in shares)						0
Options granted (in shares)						56,500
Common Stock
Subsequent Event [Line Items]
Exercise of stock options (in shares)		268,622	5,630	65,962	12,157
Subsequent event
Subsequent Event [Line Items]
Cash received from Issuance of shares, share-based payment arrangement, including option exercised	$ 95,000
Subsequent event | Loan Agreement
Subsequent Event [Line Items]
Debt convesion amount	1,700,000
Outstanding convertible debt	$ 10,000,000
Subsequent event | Common Stock
Subsequent Event [Line Items]
Exercise of stock options (in shares)	17,064
Debt converted into shares (in shares)	85,000
Debt converted into shares (in usd shares)	$ 19.64
Subsequent event | Common Stock | 2017 Plan
Subsequent Event [Line Items]
Options granted (in shares)	3,700